RESUMO
Background: There are many factors that effect on the lungs capacity and treatment process in chronic obstructive pulmonary disease [COPD]. Smoking, as a risk factor, is important in this process. The aim of this study was to evaluate the efficacy of Salmeterol on some parameters of pulmonary ventilation in smokers and non-smokers patients with COPD.
Materials and Methods: This desiccative analytical study was done on 117 patients with respiratory symptoms of COPD who had referred to an internist during 2010-2013 in Sabzevar city, Iran. Data collection methods include observation, clinical symptoms, and respiratory test [spirometry] that was performed by a physician. Before and after Salmeterol inhalation, pulmonary function tests were performed, and pulmonary parameters FEVI, FVC, FEV1% and PEF were measured and recorded. Data were analyzed using paired t test, and independent t test.
Results: Of 117 patients 75[64%] were male and 42[36%] were female. The mean age of smokers and non-smokers was 42.36 +/- 18.20 and 50.14 +/- 18.56, respectively; which was statistically significan [P<0.03]. FEV1% was significantly different in COPD patients before and after Salmeterol inhalation[97.44 +/- 10.84 and 94.75 +/- 10.81, respectively] [P<0.04]. In smokers, before Salmeterol inhalation, the mean forced expiratory volume in the first second [FEVI], was lower than nonsmokers, but after Salmeterol inhalation, was higher than nonsmokers, but not significant. Also, after Salmeterol inhalation, FEVI% was higher in non-smokers compared with smokers.
Conclusion: In smokers, COPD onset is 8 years earlier than non-smokers, and Salmeterol inhalation decreases FEVI% in COPD patients.